Key facts
- Demecan’s last known valuation is $108.8M.
- It has raised $23.4M; the latest was Later Stage VC in Aug 2024.
- Notable investors include b2venture, BMH Beteiligungs-Managementgesellschaft Hessen, Trog Hawley Capital, PHK Enterprise Family Office, Enexis (Sweden) — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Demecan
- ·The full record, as it builds
Funding rounds
No funding rounds for Demecan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Demecan
Producer and supplier of cannabis intended to be used for medicinal drug research and development process. The company specializes in the cultivation and processing of medical cannabis plants that are grown using sterilized water from a pharmaceutical reverse osmosis system indoors under complete climate control, enabling clients in the healthcare industry to avail clean and natural cannabis without pesticides and irradiation.
- Sector
- Healthcare
- HQ
- Ebersbach, Germany
- Founded
- 2017
- Employees
- 63
- Website
- demecan.de/
- Ownership
- Privately Held (backing)
Demecan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Demecan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Demecan in its N-PORT filings yet. We sweep new filings monthly.